Y. Liu, “How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?”, MS, vol. 2, no. 6, p. 2912, Dec. 2024.